Big data has the potential to provide scientists with important insights but there are still some barriers to its widespread use that need to be overcome. In this article, Paul Denny-Gouldson from IDBS tells us more…
New research from The Center for Advancing Innovation (CAI) and PatSnap — a provider of R&D analytics — has revealed that the West is starting to lose its position as leaders in the Innovation Arms Race.
Swedish based pharmaceutical development company, Kancera, has announced that unique blockers (antagonists) of the Fractalkine system have been patented, laying the foundations for the development of additional drug candidates.
Here, Steve Lyon, digital lead, Communities & Content, Allied Market Research (AMR), discusses some examples of new technology in the ADC space and the ground-breaking potential this new class of drugs will have in the treatment of cancer
In order to reduce the high level of disabilities and stroke recurrence in cases of acute ischaemic stroke (AIS) it is vital that the diverse unmet needs are addressed, according to data and analytics company, GlobalData.
Contract research organisation (CRO), Reaction Biology, has partnered with an open science drug discovery and development company, M4K Pharma, in the fight against diffuse intrinsic pontine glioma (DIPG) — a rare paediatric brain cancer.
The ability of animal studies to predict human safety has been evaluated by global information analytics business, Elsevier, through big data analysis of adverse events reported to the US FDA and EMA
A new poll from YouGov has revealed that the majority of the British public will personally step up to help the NHS advance medical research and fight diseases of the future.
In this article, Maria Andrielou, marketing & communication, and Thanos Andreou, scientific affairs, at VIO Chemicals, give their views on how to get the best out of process R&D.
In this online exclusive, Dr Karen Whiting, global head of New Product Development at BBI Solutions, looks at the evolution of the diagnostics market and how new approaches can help companies’ future-proof their products.
Research from a team led by the Technical University of Munich (TUM) has uncovered a breakthrough in peptide chemistry that may enable the administration of peptide active agents orally.
A co-founder of the company ApconiX, based in Alderley Park, has revealed his view that attitude towards safety in pre-clinical cancer drug development needs to change.
